Impact Of Obesity And High Cholesterol On The Lipid Disorder Treatment Market: An Emerging Driver Transforming The Lipid Disorder Treatment Market Landscape

The Lipid Disorder Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Projected Growth of the Lipid Disorder Treatment Market?
The lipid disorder treatment market has expanded rapidly in recent years. It will increase from $10.69 billion in 2024 to $12.09 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.2%. The growth is attributed to the rise of sedentary lifestyles, an increasing working population, greater awareness of the disease and its treatment, more desk jobs, and growing incidences of familial combined hyperlipidemia.

The lipid disorder treatment market is expected to see rapid growth, reaching $19.56 billion by 2029, with a CAGR of 12.8%. This growth is driven by rising obesity rates, the increasing prevalence of cardiovascular diseases, and the growing demand for safe and efficient treatments. Trends include advancements in drug development, product innovations, increased investments in business expansion, clinical advancements, and new technological advancements in treatment facilities.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15600

What Are the Different Lipid Disorder Treatment Market Segments?
The lipid disorder treatment market covered in this report is segmented -

1) By Drug Type: Atorvastatin, Fluvastatin, Rosuvastatin, Simvastatin, Pravastatin, Other Drugs
2) By Indication: Familial Combined Hyperlipidemia, Familial Defective Apolipoprotein B-100, Familial Dysbetalipoproteinemia, Familial Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia, Other Indications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:
1) By Atorvastatin: Generic Atorvastatin, Brand-Name Atorvastatin ( Lipitor)
2) By Fluvastatin: Generic Fluvastatin, Brand-Name Fluvastatin ( Lescol)
3) By Rosuvastatin: Generic Rosuvastatin, Brand-Name Rosuvastatin ( Crestor)
4) By Simvastatin: Generic Simvastatin, Brand-Name Simvastatin ( Zocor)
5) By Pravastatin: Generic Pravastatin, Brand-Name Pravastatin ( Pravachol)
6) By Other Drugs: Ezetimibe, Pcsk9 Inhibitors ( Alirocumab, Evolocumab), Fibrates ( Gemfibrozil, Fenofibrate), Niacin (Vitamin B3), Omega-3 Fatty Acids ( Icosapent Ethyl)

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15600&type=smp

What Are the Primary Drivers Shaping the Lipid Disorder Treatment Market?
The rising cases of obesity and high cholesterol are expected to drive the expansion of the lipid disorder treatment market. Obesity, characterized by excessive fat accumulation, and high cholesterol, marked by elevated cholesterol levels in the blood, present significant health risks. These conditions are becoming more prevalent due to unhealthy diets, sedentary lifestyles, genetic factors, and environmental influences. Lipid disorder treatments play a critical role in managing obesity and high cholesterol by integrating pharmacological solutions with lifestyle changes, weight management strategies, education, and multidisciplinary care. For example, in May 2022, the World Obesity Atlas 2022 by the World Obesity Federation projected that by 2030, one billion people globally would be living with obesity, including 1 in 5 women and 1 in 7 men, and by 2035, this figure would rise to 4 billion people, or 51% of the global population. As such, the growing prevalence of obesity and high cholesterol is contributing to the growth of the lipid disorder treatment market.

Which Companies Are Leading in the Lipid Disorder Treatment Market?
Major companies operating in the lipid disorder treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca Plc, Fresenius SE & Co. KGaA, Abbott Laboratories Inc., Novartis AG, GlaxoSmithKline Plc, Wockhardt Ltd., Eli Lilly and Company, Amgen Inc., Boehringer-Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Kaneka Corporation, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Emcure Pharmaceuticals Limited, Kowa Pharmaceuticals America Inc., Concord Biotech Limited, Biocon Ltd., Ranbaxy Laboratories Limited

What Lipid Disorder Treatment Market Trends Are Gaining Traction Across Different Segments?
Prominent businesses in the lipid disorder treatment market are focusing on the creation of proprotein convertase subtilisin type 9 (PCSK9) inhibitors to fulfill the requirement for more efficient and targeted treatments to effectively control high cholesterol levels. PCSK9 inhibitors work by improving the elimination of LDL cholesterol from the blood, thus lessening the chance of cardiovascular incidents in high-risk individuals. An example of this is when Regeneron Pharmaceuticals Inc., a biotechnology firm based in the US, acquired approval in March 2024 for the use of their Praluent (alirocumab) injection from the U.S. Food and Drug Administration (FDA) to tackle heterozygous familial hypercholesterolemia (HeFH) in children aged 8 and above. The distinctive benefit of the Praluent injection is its capacity to obstruct the connection of PCSK9 to the LDL receptor, augmenting the number of LDL receptors on the liver cell surfaces, and thus aiding in the clearance of LDL and decreasing LDL-C levels in the blood.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/lipid-disorder-treatment-global-market-report

What Are the Top Revenue-Generating Geographies in the Lipid Disorder Treatment Market?
North America was the largest region in the lipid disorder treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lipid disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Lipid Disorder Treatment Market?
2. What is the CAGR expected in the Lipid Disorder Treatment Market?
3. What Are the Key Innovations Transforming the Lipid Disorder Treatment Industry?
4. Which Region Is Leading the Lipid Disorder Treatment Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.